737x180 Biosimilars
Biosimilars have attracted a great deal of interest recently and are seen by some as the new generic frontier. It is widely thought that lower levels of competition will lead to higher margins in an industry notorious for its generally low margins on commodity generics.
Biosimilar manufacturers are also looking to strengthen their long term strategy, with many planning to produce improved biobetters to help compete against second generation innovator biologic drugs. Many believe that biobetters, with their improved characteristics are a more exciting and favourable proposition than biosimilars - will offer medical advantages along with a better price.
Hear from experts in this field discuss the latest developments in legislation, regulation, technology and commercial strategies to succeed in this highly competitive evolving market.
Visit our website for more information and to view the full programme
http://www.smi-
Key presentations include:
Biosimilar CMC development - an innovator's point of view
Matthias Hoepfner, VP, Head GRA Global CMC & Change Management, Bayer Schering Pharma
Biosimilars in the clinic - How physicians view biosimilars
David Goldsmith, Consultant Nephrologist, St Thomas' Hospital
EMA guidelines for biosimilar monoclonal antibodies
Robert Blakie, Director of Regulatory Affairs and General Manager (UK), ERA Consulting
• Leveraging biosimilars licensing opportunities
Rahul Padhye, Head, Corporate Development, Reliance Life Sciences
• roving biosimilar delivery systems to compete with second-gen innovator products
Keith Powell, CEO, PolyTherics
With a case study focused agenda and delegates from companies including Hospira, Biogen Idec, Ranbaxy, GlaxoSmithKline, Synthon BV, Pfizer, Reliance Life Sciences, Bayer Schering Pharma, Ablynx and more, you'll gain a unique insight into this rapidly evolving industry from the key opinion leaders in the field.
Photo:
http://www.prlog.org/
